Drug intelligence / Profile preview

pinacidil

Development stage: Discontinued
Modality: Small Molecules
Administration: Oral, Topical

Overview

Pinacidil is a cyanoguanidine small molecule antihypertensive drug that acts as an ATP-sensitive potassium channel opener in vascular smooth muscle cells. By increasing potassium permeability, it causes peripheral vasodilatation of arterioles and decreases peripheral vascular resistance, resulting in reduced blood pressure. Pinacidil was approved by the FDA in 1989 but has since been discontinued. It is classified as a guanidine derivative and was primarily indicated for the treatment of hypertension[1][2][4][5].

Brand names: Pindac
Other names: pinacidil hydratepinacidil monohydrate

Targets

SUR1 (Sulfonylurea receptor 1)

Beyond the preview

Go deeper on pinacidil.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on pinacidil.

Explore the full profile